A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence

A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence

Abstract Relapsed and/or refractory acute myeloid leukemia (AML) post-allogeneic hematopoietic cell transplantation (HCT) is usually fatal. We previously reported that post-HCT immunotherapy with Epstein-Barr virus (EBV)-specific donor CD8+ T cells engineered to express a Wilms Tumor Antigen 1-speci...

Full description

Saved in:
Bibliographic Details
Main Authors: Francesco Mazziotta, Lauren E. Martin, Daniel N. Egan, Merav Bar, Sinéad Kinsella, Kelly G. Paulson, Valentin Voillet, Miranda C. Lahman, Daniel Hunter, Thomas M. Schmitt, Natalie Duerkopp, Cecilia C. S. Yeung, Tzu-Hao Tang, Raphael Gottardo, Yuta Asano, Elise C. Wilcox, Bo Lee, Tianzi Zhang, Paolo Lopedote, Livius Penter, Catherine J. Wu, Filippo Milano, Philip D. Greenberg, Aude G. Chapuis
Format: Article
Language:English
Published: Nature Portfolio 2025-06-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-60394-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-60394-0

Similar Items